Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals, Inc. Announces Achievement Of CART Milestones With Taisho Pharmaceutical Co., Ltd
Arena Pharmaceuticals, Inc. Announces Achievement Of CART Milestones With Taisho Pharmaceutical Co., Ltd SAN DIEGO, Oct. 23 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its May 29, 2000 research agreement with Taisho Pharmaceutical Co., Ltd.,
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Receipt of First CART Milestone Payments From Eli Lilly and Company
Arena Pharmaceuticals, Inc. Announces Receipt of First CART Milestone Payments From Eli Lilly and Company SAN DIEGO, Sept. 25 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that under the terms of its April 14, 2000 research collaboration and license agreement with Eli
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Grant of First U.S. Patent; Method Claims Directed to CART-Discovered Inverse Agonist Compounds
Arena Pharmaceuticals, Inc. Announces Grant of First U.S. Patent; Method Claims Directed to CART-Discovered Inverse Agonist Compounds SAN DIEGO, Aug. 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the issuance of United States Patent Number 6,107,324 entitled
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option
Arena Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option SAN DIEGO, Aug. 10 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriters led by ING Barings LLC, Prudential Securities Incorporated, and SG Cowen Securities Corporation, have exercised
View HTML
Toggle Summary Lexicon Genetics and Arena Pharmaceuticals Target New Receptors for Pharmaceutical Development
-- In vivo Screens Detect Modulators of G-Protein Coupled Receptor Activity
View HTML
Toggle Summary New issues ride investor dreams amid Nasdaq selloff
By Denise Duclaux
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Announces Initial Public Offering Of 6,000,000 Shares of Common Stock
Arena Pharmaceuticals, Inc. Announces Initial Public Offering Of 6,000,000 Shares of Common Stock SAN DIEGO, July 28 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its initial public offering of 6,000,000 shares of its common stock was priced at $18 per share, above
View HTML
Toggle Summary Arena Pharmaceuticals, Inc. Listed on Nasdaq National Market System Following Initial Public Offering
Arena Pharmaceuticals, Inc. Listed on Nasdaq National Market System Following Initial Public Offering July 28, 2000--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA - news ) was admitted to the Nasdaq National Market System following its initial public offering of 6 million shares at $18 per share.
View HTML
Toggle Summary Arena prices 6 mln IPO at $18/shr, above range
Arena prices 6 mln IPO at $18/shr, above range NEW YORK, July 27 (Reuters) - Arena Pharmaceuticals Inc. (Nasdaq: ARNA - news ) sold 6 million shares at $18 per share, above the estimated price range, in its initial public offering on Thursday, according to the lead underwriters.
View HTML
Toggle Summary Arena Pharmaceutcals raises IPO to 6 mln shares
Arena Pharmaceutcals raises IPO to 6 mln shares WASHINGTON, July 25 (Reuters) - Arena Pharmaceuticals Inc. on Tuesday raised its initial public offering (IPO) to 6 million shares of common stock from 5 million shares. The company, which says it has developed technology that identifies drug
View HTML